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Abstract 
Background 
Candida albicans infections have become increasingly recognised as being biofilm related. 
Recent studies have shown that there is a relationship between biofilm formation and poor 
clinical outcomes in patients infected with biofilm proficient strains. Here we have 
investigated a panel of clinical isolates in an attempt to evaluate their phenotypic and 
transcriptional properties in an attempt to differentiate and define levels of biofilm formation. 
Results 
Biofilm formation was shown to be heterogeneous; with isolates being defined as either high 
or low biofilm formers (LBF and HBF) based on different biomass quantification. These 
categories could also be differentiated using a cell surface hydrophobicity assay with 24 h 
biofilms. HBF isolates were more resistance to amphotericin B (AMB) treatment than LBF, 
but not voriconazole (VRZ). In a Galleria mellonella model of infection HBF mortality was 
significantly increased in comparison to LBF. Histological analysis of the HBF showed 
hyphal elements intertwined indicative of the biofilm phenotype. Transcriptional analysis of 
23 genes implicated in biofilm formation showed no significant differential expression 
profiles between LBF and HBF, except for Cdr1 at 4 and 24 h. Cluster analysis showed 
similar patterns of expression for different functional classes of genes, though correlation 
analysis of the 4 h biofilms with overall biomass at 24 h showed that 7 genes were correlated 
with high levels of biofilm, including Als3, Eap1, Cph1, Sap5, Plb1, Cdr1 and Zap1. 
Conclusions 
Our findings show that biofilm formation is variable amongst C. albicans isolates, and 
categorising isolates depending on this can be used to predict how pathogenic the isolate will 
behave clinically. We have shown that looking at individual genes in less informative than 
looking at multiple genes when trying to categorise isolates at LBF or HBF. These findings 
are important when developing biofilm-specific diagnostics as these could be used to predict 
how best to treat patients infected with C. albicans. Further studies are required to evaluate 
this clinically. 
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Background 
Bloodstream infections (BSI) caused by Candida species remain a frequent cause of 
morbidity and mortality, particularly within the immunocompromised population [1,2]. 
Overall, Candida species have been identified as the most common fungal pathogen found in 
bloodstream infections in the United States, and are the fourth most common organism 
responsible for all BSI, and are the third most common within the intensive care unit (ICU) 
[2]. Candidaemia is often associated with the ability of Candida to adhere to and form 
biofilms on indwelling medical devices, such as central venous catheters (CVC) and 
prosthesis [3,4]. Biofilms are a population of microorganisms attached to one another and/or 
a surface, surrounded by an extracellular matrix (ECM) [5]. 
A defining feature of biofilms is their resistance to antimicrobial therapy, with higher drug 
concentrations required to kill biofilms and their dispersed cells when compared to equivalent 
free-floating planktonic cells [5-7]. Another feature of C. albicans biofilms is their enhanced 
pathogenicity. For example, cells detaching from biofilms have been shown to be more 
cytotoxic than their planktonic counterparts and significantly increase mortality within a 
murine model of infection [7]. These observations have been demonstrated clinically, where a 
significant association was observed between C. albicans biofilm formation and mortality 
rates in candidaemia patients [8]. 
Whilst there is growing evidence of the importance of Candida biofilms in clinical medicine, 
not all clinical isolates are able to form biofilms. There is therefore a fundamental gap in 
understanding exactly what drives biofilm formation and its clinical implications. 
Establishing methods to differentiate these isolates is challenging, as many studies rely on 
either metabolic assays or biomass, and these frequently use a variety of different substrates 
and media [9-12]. Therefore, comparison between these studies is not possible, and further 
interpretation of the data to improve clinical management both for diagnostics and antifungal 
therapy is limited. The purpose of this study was therefore to investigate and characterise 
biofilm formation by clinical isolates of C. albicans using standard methodologies and 
subsequently analyse biofilm subsets phenotypically and transcriptionally. Here we report 
that C. albicans clinical isolates form biofilms that are heterogeneous, and this is associated 
with altered antifungal drug sensitivity and pathogenic potential. 
Results 
Candida albicans clinical isolates exhibit heterogeneous biofilm formation 
C. albicans bloodstream isolates displayed heterogeneity with respect to their biofilm 
biomass when grown in RPMI (Figure 1A). RPMI was shown to support the optimal growth 
of C. albicans over 24, 48 and 72 h (Additional file 1: Figure S1). Isolates were categorised 
as low biofilm formers (LBF) or high biofilm formers (HBF) if their biomass absorbance 
were less than the first quartile (Q1 OD570 = 0.565) or greater than the third quartile (Q3 OD570 
= 1.682), respectively. Those isolates in between the first and third quartile (Q1-Q3) were 
defined as intermediate biofilm formers. When HBF were stained with crystal violet (cv), the 
extent of the biofilm formation was observed macroscopically, where the bottom of the well 
was clearly covered with cellular biomass (Figure 1A). In contrast, minimal staining was 
retained on isolates classed as LBF, as demonstrated by the well remaining almost colourless. 
We analysed a subset of isolates from the LBF and HBF group (n = 3) using dry weight 
measurements and confirmed our previous observations that biofilm biomass was 
significantly greater in isolates termed HBF (p = 0.0023) (Figure 1B). These differences are 
clearly evident when viewed under a SEM at low (Figure 1C [i, iii]) and high magnification 
(Figure 1C [ii, iv]). LBF isolates were characterised by a predominance of yeast cells and 
lack of hyphal cells (Figure 1C i, ii). In contrast, C. albicans HBF were highly filamentous 
with a multi-dimensional structure with very few yeast cells (Figure 1C iii, iv). 
Figure 1 Candida albicans clinical isolates vary in their ability to form biofilms. Forty-
two C. albicans bloodstream isolates were used to evaluate biofilm formation of strains 
derived from a clinical setting. (A) Standardised C. albicans (1 × 106 cells/mL) in RPMI-
1640 were grown in flat-bottomed 96 well microtitre plates for 24 h at 37°C. Mature biofilms 
were carefully washed with PBS, allowed to air dry and biomass quantified by staining with 
0.05% w/v crystal violet solution. The biofilms were washed and destained with 100% 
ethanol. Biomass was quantified spectrophotometrically by reading absorbance at 570 nm in 
a microtitre plate reader (FluoStar Omega, BMG Labtech). Eight replicates were used for 
each isolate and was carried out on two separate occasions, with the mean of each 
represented. C. albicans LBF (square), HBF (triangle) and IBF (circle) were defined by the 
upper and lower quartiles, as shown by crystal violet stained biofilms. (B) Three C. albicans 
LBF and HBF were standardised (1 × 106 cells/mL) in RPMI-1640 and grown in 12 well 
plates for 24 h at 37°C. Biofilms were washed with PBS, biomass scraped and passed through 
0.22 µm filters before the filters containing the biofilms were dried at 37°C for 24 h. Biofilm 
dry weight was then measured for LBF and HBF, in triplicate on three separate occasions. 
Data represents mean ± SD with significance **p < 0.005. (C) One C. albicans LBF (i, ii) 
and HBF (iii, iv) were grown on Thermanox™ coverslips for 24 h at 37°C. Biofilms were 
then processed and viewed on a JEOL JSM-6400 scanning electron microscope and images 
assembled using Photoshop software. Note the lack of biomass and hyphal cells in LBF. 
Scale bars represent 20 µm and 5 µm for 1000× (i, iii) and 3000× (ii, iv) magnifications, 
respectively. 
Biofilm phenotype is affected by cell surface hydrophobicity (CSH) 
The CSH of LBF and HBF isolates was quantified to determine whether it played a role in 
biofilm forming ability [13]. Figure 2 illustrates that the hydrophobicity of an isolate 
significantly alters its ability to form a biofilm. For LBF the CSH increased by 32% and 31% 
in 4 h (p < 0.05) and 24 h (p < 0.0005) biofilms, respectively, when compared to planktonic 
cells. This trend was also observed in isolates with HBF where CSH increased by 50% in 4 h 
(p < 0.0001) biofilms and 81% in 24 h (p < 0.0001) biofilms, when compared with planktonic 
counterparts. Furthermore, a significant increase in CSH was found in isolates with HBF 
between early (4 h) and mature (24 h) phases of biofilm development, where hydrophobicity 
increased by 31% (p < 0.001). When the hydrophobicity of LBF and HBF was compared, 
CSH was significantly increased by 41% in HBF isolates at 24 h (p < 0.0001); however, no 
significant difference was observed between isolates with LBF and HBF in planktonic cells 
and 4 h biofilms. 
Figure 2 Cell surface hydrophobicity impacts biofilm phenotype. Ten C. albicans LBF 
and HBF were standardised (1 × 106 cells/mL) in RPMI-1640 and grown in 75 cm2 flasks for 
4 and 24 h. Biofilms were washed with PBS, biomass scraped in to YPD media and 
standardised to OD590nm 1.0 before xylene was added to each sample. Planktonic cells were 
also standardised to OD590nm 1.0. Samples were allowed to separate into two phases and the 
OD590nm of the lower aqueous layer was measured (i). A visual representation hydrophobicity 
is shown for planktonic LBF (ii) and HBF (iii), 4 h biofilms LBF (iv) and HBF (v) and 24 h 
biofilms LBF (vi) and HBF (vii). Note the cloudy upper layer denoted by arrows showing 
hydrophobic cells. Ten isolates from each group were measured on two separate occasions. 
Data represented mean ± SD. Significant differences between LBF and HBF were observed 
when 4 and 24 h biofilms were compared to their planktonic counterparts (*p < 0.05, ***p < 
0.0001, ###p < 0.0001). Furthermore, significant differences were found between 4 and 24 h 
in HBF (†††p < 0.0001) and between LBF and HBF at 24 h (§§§p < 0.0001). 
Amphotericin B activity is impacted by biofilm phenotype 
Sessile antifungal testing was performed on C. albicans isolates with LBF and HBF to 
determine if one group were more susceptible to VRZ or AMB treatment. VRZ was 
ineffective against all biofilms tested, showing no difference in activity against LBF and HBF 
(data not shown). However, a dose-dependent effect was evident in all isolates tested with 
AMB (Figure 3). Moreover, a significant difference was observed between LBF and HBF 
treated with 0.25 – 32 mg/L AMB (p < 0.05). LBF and HBF isolates both had a MIC50 of 
0.25 mg/L AMB, yet isolates with LBF were significantly less viable than those with HBF at 
this concentration (p = 0.0307). In addition, LBF isolates achieved an ~80% kill at 4 mg/L, 
whereas HBF required 32 mg/L to reach the same kill. No significant differences were 
observed in the growth rates of either set of LBF and HBF isolates (data not shown). 
Figure 3 Amphotericin B sensitivity is significantly impacted by biofilm formation. Ten 
isolates with LBF and HBF were standardised to 1 × 106 cells/mL in RPMI-1640 and grown 
as biofilms in flat-bottomed 96 well microtitre plates for 24 h. Biofilms were washed with 
PBS before treated with 2 fold serial dilutions of amphotericin B for 24 h. Biofilms were 
washed and metabolic activity measured using the XTT metabolic assay with absorbance 
read at 492 nm. Each isolate was tested in duplicate, on three separate occasions with data 
represented by mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
In vivo pathogenicity is affected by biofilm phenotype 
We next analysed the impact of the isolates ability to form biofilms based upon the severity 
of infection using a previously described G. mellonella model. The average rate of killing by 
three HBF, three LBF and a reference strain (SC5314) of C. albicans were calculated to plot 
a survival curve. Survival data showed a significant difference in the killing of larvae 
between HBF and LBF (p < 0.0001 [Figure 4A]). After 2 and 6 days, respectively, >50% and 
100% larval death was recorded for HBF isolates, whereas larvae infected with LBF only 
achieved 20% killing after 7 days challenge. The reference strain SC5314 achieved 50% and 
100% larval death by day 4 and 7, respectively. Similar kill rates to that of HBF were 
observed in the type strain however, when compared to LBF there was a significant 
difference in larval mortality (p = 0.0005). 
Figure 4 C. albicans HBF have a significant impact on morbidity and mortality rate in 
vivo. Larvae of G. mellonella were infected with C. albicans LBF or HBF at 1 × 105 
CFU/larva and monitored over a period of 7 days (A). Kaplan-Meier plots of G. mellonella 
survival after injection of C. albicans demonstrated a strain dependant variation in 
pathogenicity in vivo. Groups of HBF and LBF clinical isolates were compared to each other 
and to the SC5314 type strain. The HBF isolates resulted in higher killing rate compared to 
LBF and SC5314. In contrast, LBF isolates exhibit a slower rate of kill and 100% mortality 
did not occur within 7 days. PBS injected larvae were included as a negative control. (B) 
Infected larvae were formalin fixed and sectioned for histology analysis. At 24 h, LBF 
infected larvae (i) had several melanisation spots and nodules were present mainly under the 
cuticle and in the peripheral fat body (Feulgen staining, 20× original magnification (o.m.); 
inset: 4× o.m.), whereas HBF infected larvae (iv) had larger nodules with a greater melanin 
deposition characterised by the recruitment in the external layers of a huge number of 
haemocytes (20× o.m.; inset: 10× o.m). At 48 h, LBF (ii) small nodules containing both yeast 
and some hyphae were observed deeper in the larval tissues, sometimes reaching the external 
part of the gut wall (PAS staining, 20× o.m.; inset: 10× o.m), with HBF (v) having elongated 
hyphae targeting the intestinal walls (PAS staining, 40× o.m.; inset: 10× o.m.) At 72 h, LBF 
(iii) showed segmental invasion of the gut walls (PAS staining, 20× o.m.; inset: 10× o.m.) 
however, HBF (vi) displayed hyphae endoluminal invasion after breaching the intestinal wall 
(PAS staining, 40× o.m.; inset: 10× o.m.) with few yeast cells. 
Host-pathogen interactions in this model were then investigated by microscopically observing 
the morphology of the infected larvae at 24, 48 and 72 h post-infection with C. albicans HBF 
and LBF (Figure 4B). At 24 h in both the LBF (Figure 4Bi) and HBF (Figure 4Biv), the 
nodule formation and melanin deposition were mainly observed under the cuticle and in the 
fat body, with mild to strong melanisation observed in the centre of the nodules, together with 
the presence of yeast cells and/or hyphae. The LBF nodules were smaller in dimension and 
dispersed mainly in the subcuticle area (Figure 4Bi), whereas the HBF nodules had a stronger 
melanisation with the tendency to converge in large aggregates, and were localised more 
deeply within the fat body (Figure 4Biv). At 48 h, the LBF were confined to the external part 
of the visceral organs, with a spot-like distribution (Figure 4Bii); whereas the HBF were 
found to display a pronounced filamentation all around the intestinal wall, with a PAS 
positive matrix visible surrounding the hyphae (Figure 4Bv). Furthermore at 72 h, there was a 
substantial invasion of both the gastrointestinal tract and the tracheal system with damaged 
gut epithelium, where yeast and hyphal cells both observed in the HBF infection (Figure 
4Bvi). In contrast, a segmental invasion of the intestinal wall (Figure 4Biii) was observed 
with LBF infection and the progression of the infection was to a lesser extent than that by the 
HBF. Table 1 summarises the localisation and characterisation of the nodules with LBF and 
HBF infected larvae. Changes in the fat body morphology and composition including 
vacuolisation and haemocyte recruitment, were detected during the course of the infection 
and were more evident in the HBF. 
Table 1 Characteristics and localisation of nodules found in infected G. mellonella 
larvae 
 Nodules 
 Size Melanisation Encapsulation Confluence Fungal morphology Localisation 
 Yeast cells Hyphae SC FB PI PT 
LBF Small + + - +++ +* + + ++ - 
HBF Large ++, +++ +++ + + +++** ++ ++ +++ + 
SC: subcuticle, FB: fat body, PI: paraintestinal, PT: paratracheal. 
*short squat hyphae, **long tangled hyphae often embedded in an extracellular matrix. 
Transcriptional heterogeneity is associated with biofilm phenotype 
C. albicans clinical isolates defined as LBF and HBF were further assessed at a 
transcriptional level and the expression of genes related to biofilm formation was 
investigated. ACT1 was used as the housekeeping gene and was shown to be stably expressed 
throughout all biofilm conditions. Figure 5 illustrates the levels of gene expression of LBF (n 
= 10) versus HBF (n = 10) at both (A) 4 and (B) 24 h. Overall, the majority of the genes 
tested followed a trend of up-regulation in HBF compared to LBF. However, statistically 
significant differences were observed in the glycosylated mannoproteins MNN4 (p = 0.0313) 
and MNT2 (p = 0.0044) at 4 h, where expression was increased by ~2 fold. Furthermore, the 
resistance gene CDR1 was significantly increased in HBF by 4- and 6-fold at 4 h (p = 0.0113) 
and 24 h (p = 0.0239), respectively (Additional file 2: Table S1). 
Figure 5 Genes associated with C. albicans biofilm development are up-regulated in 
HBF. Ten C. albicans isolates with LBF and HBF were standardised to 1 × 106 cells/mL in 
RPMI-1640 and grown as biofilms in 24 well microtitre plates for 4 (A) and 24 h (B) at 37°C. 
Biofilms were washed with PBS and RNA extracted using the TRIzol method, cDNA 
synthesised and real-time PCR used to measure the expression of genes related to C. albicans 
biofilm formation. Percentage of gene expression is shown as log10 mean ± SD, relative to 
housekeeping gene ACT1. All strains were assessed in duplicate and included appropriate no 
RT and non-template controls. *p < 0.05, **p < 0.005. 
Clustering the expression of 23 selected genes from 5 different functional groups in a heat 
map showed their relationship with one another and their variable expression in LBF and 
HBF over time (Figure 6). Here we found the adhesion genes ALS3 and HWP1 were closely 
related and highly expressed, particularly in HBF isolates at 4 and 24 h. Furthermore, genes 
from different functional groups were closely related to one another irrespective of whether 
LBF or HBF, such as the proteinase SAP5 and the adhesion genes ALS5 and EAP1. The 
remaining SAP genes were all closely related to one another, and interestingly the resistance 
gene MDR1 and the cell wall mannoprotein OCH1. Further analysis of SAP3 showed an 
increase in transcription within LBF at 24 h, despite no differences being observed at 4 h. In 
contrast, SAP5 expression was consistently high at 4 and 24 h within HBF. 
Figure 6 Clustering analysis identified the transcriptional relationship of biofilm 
specific genes. Percentage expression of each gene was also assessed by clustering and heat 
map analysis using GenEx software. Data was log transformed and mean values were used 
for heat map construction. Increased expression of genes is shown by red and a decrease is 
represented by green. 
Analysis of Spearman rho coefficients found that out of 23 selected genes, 7 including those 
related to adhesion (ALS3, EAP1), filamentation (CPH1), hydrolytic enzymes (SAP5, PLB1) 
and resistance (CDR1 and ZAP1) showed a significant positive correlation (p < 0.05) with cv 
biomass data at 4 h (Table 2). Further analysis of the relationship between these seven genes 
and all the other genes tested presented various correlations (marked bold in Table 2). For 
example, PLB1 was significantly correlated with all other genes tested (94.11%) except 
ZAP1, followed by CPH1 (76.47%), SAP5 (76.47%), EAP1 (64.71%), CDR1 (41.17%), ALS3 
(35.29%) and ZAP1 (11.76%). Correlation of individual genes with one another at the 4 h 
time point showed that PLB1, CPH1, MNN4 and HWP1 all correlated with 5 of the 7 key 
genes defined above. Notably, 24 h gene expression revealed very few significant 
correlations other than cv. In fact, a significant negative correlation was found between SAP3 
and the biomass data (Rho = −0.465, p = 0.045). Furthermore, SAP3 was positively correlated 
with MNT2 (Rho = 0.468, p = 0.043) and SAP4 (Rho = 0.460, p = 0.048). 
Table 2 C albicans biomass correlates with biofilm-related gene expression 
4 h Correlationsa ALS3 EAP1 CPH1 SAP5 PLB1 CDR1 ZAP1 
CV Rho= .529* .608** .534* .539* .483* .647** .515* 
 p = .029 .010 .027 .026 .050 .005 .035 
ALS1 Rho= .240 .529* .542* .336 .608** .382 .250 
 p = .353 .029 .025 .188 .010 .130 .333 
ALS3 Rho= 1.000 .385 .708** .544* .593* .779** .365 
 p =  .127 .001 .024 .012 .000 .149 
ALS5 Rho= .229 .538* .644** .607** .681** .145 .214 
 p = .378 .026 .005 .010 .003 .579 .410 
EAP1 Rho= .385 1.000 .544* .490* .860** .537* .279 
 p = .127  .024 .046 .000 .026 .277 
HWP1 Rho= .868** .338 .821** .571* .532* .615** .201 
 p = .000 .184 .000 .017 .028 .009 .439 
MNN4 Rho= .350 .554* .645** .537* .672** .493* .309 
 p = .168 .021 .005 .026 .003 .045 .228 
PMR1 Rho= .333 .635** .527* .534* .784** .233 .377 
 p = .191 .006 .030 .027 .000 .368 .135 
BCR1 Rho= .262 .250 .539* .566* .485* .306 .522* 
 p = .309 .333 .026 .018 .048 .232 .032 
CPH1 Rho= .708** .544* 1.000 .833** .748** .547* .321 
 p = .001 .024  .000 .001 .023 .209 
EFG1 Rho= .257 .520* .576* .645** .605* .409 .392 
 p = .319 .033 .016 .005 .010 .103 .119 
TUP1 Rho= .713** .397 .397 .463 .544* .684** .444 
 p = .001 .115 .115 .061 .024 .002 .074 
SAP1 Rho= .356 .523* .794** .744** .730** .251 .413 
 p = .160 .031 .000 .001 .001 .332 .100 
SAP2 Rho= .091 .554* .478 .417 .654** .172 .292 
 p = .729 .021 .052 .096 .004 .510 .256 
SAP5 Rho= .544* .490* .833** 1.000 .676** .395 .539* 
 p = .024 .046 .000  .003 .117 .026 
SAP6 Rho= .371 .772** .637** .627** .869** .320 .284 
 p = .143 .000 .006 .007 .000 .211 .269 
PLB1 Rho= .593* .860** .748** .676** 1.000 .532* .434 
 p = .012 .000 .001 .003  .028 .082 
CDR1 Rho= .779** .537* .547* .395 .532* 1.000 .262 
 p = .000 .026 .023 .117 .028  .309 
ZAP1 Rho= .365 .279 .321 .539* .434 .262 1.000 
 p = .149 .277 .209 .026 .082 .309  
* Correlation is significant at the 0.05 level (2-tailed), ** Correlation is significant at the 0.01 level (2-tailed). 
a. List wise N = 17. 
Discussion 
C. albicans is an important pathogen. It is the fourth most common organism isolated from 
total bloodstream infections [2] and continues to carry a high mortality. The presence of 
medical devices such as central venous catheters (CVC’s) are known to be important risk 
factors [14] suggesting that biofilm formation is a key feature in the pathogenesis of 
candidaemia. The past decade has seen a significant leap in our knowledge and understanding 
of the biology of C. albicans biofilms, particularly with respect to the molecular basis of their 
development and homeostasis [15]. However, in the clinical setting it is generally assumed 
that all C. albicans isolates have the capacity to form biofilms, but often with little regard to 
individual differences within the species when managing the infection. Here we demonstrate 
that C. albicans display heterogeneous biofilm characteristics, and these strain differences 
have important implications with respect to treatment and pathogenicity. 
Previous studies have reported very defined categories in their analysis of association with 
clinical outcomes, i.e. biofilm formers and non-biofilm formers [8,16]. However, these 
important studies fail to take into account the heterogeneous nature of individual clinical 
isolates forming biofilms, which based on their metabolic XTT values can range from 0.125 
to 1.358 [16]. When looking for clinical correlations with these phenotypes then important 
information can be missed, as the isolates at either end of the biofilm forming spectrum may 
lead to different clinical outcomes. We therefore aimed to evaluate and categorise C. albicans 
biofilms into distinct levels of biofilm formation to determine if their biological features were 
significantly different. Initially we categorised biofilms grown in RPMI using a biomass stain 
[17] and followed this up with dry weight analysis, which differentiated clinical isolates into 
defined groupings. This approach was used in preference to metabolic assays due to the 
highly variable nature of XTT from strain to strain [16]. Moreover, XTT’s mainstay 
usefulness is limited to antifungal drug testing of biofilms [11,18]. Our classification, based 
initially on biomass, was supported by observations on a macro- and microscopic level where 
it was clear that numerous cells consisting of hyphae and yeasts were visible in HBF, whereas 
scant layers of yeast cells were observed for LBF. We also investigated CSH as an additional 
biofilm positive feature, as previous studies have also shown a link between biofilm biomass 
and CSH [13,19]. This study confirms that CSH impacts different phases of biofilm 
development, which is in agreement with previous work where it was shown that cells 
dispersed from mature biofilms were more hydrophobic than those dispersed from earlier 
stages of biofilm development [20]. Furthermore, it has been shown hydrophobic cells are 
more adherent [21], and therefore it is unsurprising that CSH was increased in HBF isolates. 
Based on our overall approach to biofilm categorisation we can be confident in the 
phenotypes selected for further detailed analysis. We do however concede there are caveats to 
defining levels of biofilm, and this requires further work and collaboration between groups to 
establish a standardised method. 
One of the key defining features of C. albicans biofilms is their insensitivity to sterol active 
antifungal agents [5]. We examined azole treatment, which unsurprisingly demonstrated poor 
activity overall with no group differences, presumably through adaptive resistance 
mechanisms as previously described [22-24]. Notably, AMB was less effective against HBF 
biofilms than LBF, which we hypothesise is due to the inability of the compound to permeate 
easily throughout the dense physical structure of the cells encased within ECM [25]. We 
purposely excluded echinocandins from this study as these have been shown to be an 
effective anti-biofilm antifungals, therefore quantifying differences in activity against the two 
populations would be difficult [26]. These observations may have implications to whether a 
patient responds to antifungal therapy, as Tumbarello and colleagues (2012) demonstrated 
that inadequate antifungal therapy (azoles) and the presence of an indwelling venous catheter 
were key predictors of patient mortality and hospital length of stay in patients infected with 
biofilm forming isolates [8]. Guidelines have also suggested that removal of the catheter is an 
important factor in improving clinical outcomes, again supporting the notion that biofilm 
formation has a crucial role in clinical outcomes [27,28]. Given the importance of these 
infections, efficient and appropriate treatment in candidaemia cases has been highlighted 
[29,30], as failure to treat quickly and effectively has profound consequences on mortality 
statistics [31]. 
We decided to test the hypothesis that clinical isolates capable of forming robust biofilms 
were more pathogenic, which may be a reason for their apparent role in infections with 
increased mortality [16]. Previous experimental work has shown that cells dispersed from 
biofilms are more cytotoxic and kill mice quicker than the equivalent planktonic cells [7]. 
Using a G. mellonella model we showed that HBF isolates caused significantly greater 
mortality rates than LBF isolates, a finding supported elsewhere [32]. In addition, another 
study investigated the virulence of C. albicans isolates with varying levels of biofilm 
formation and found that mice infected with a LBF had increased survival rates compared to 
isolates that were infected with HBF [33]. Histological analysis of the infected larvae 
displayed similar cell morphology of yeast and filamentous hyphae as observed in SEM 
images of LBF and HBF, respectively. This is in agreement with a previous study that 
showed filamentation plays a role in killing G. mellonella larvae [34]. 
Filamentous growth is a characteristic feature of C. albicans biofilm formation. Defective 
hyphal formation through deletion of EFG1 has been shown to lead to low levels of biofilm 
growth [35]. Given our growing knowledge of key biofilm related genes we decided to 
investigate transcriptional changes to determine whether these are truly represented amongst 
clinical isolates, and therefore could be used as a more robust way to categorise biofilm 
formation and as potential diagnostic targets of HBF isolates. ACT1, the stably expressed 
housekeeping gene, as reported elsewhere [36-38], enabled these relative comparisons. 
Regulation of biofilm related genes were shown to influence an isolates biomass within 
clinical isolates, echoing work carried out by other groups [39,40]. Cluster analysis of the 
selected biofilm related genes showed a good association with functional classes of genes, 
such as adhesins and proteinases, suggesting that both LBF and HBF had conserved pathways 
in the basic developmental phases of biofilm growth. However, individual gene expression 
profiles were inconclusive, showing very few clear independent significant differences, 
though gene expression proved interesting at 4 h. We investigated the overall biomass at 24 h 
and examined how 4 h gene expression related to this. Overall HWP1 was the most highly 
regulated at this time point in both LBF and HBF, as has been shown elsewhere [39], though 
no significant differences between the populations were observed. Seven other genes were 
however shown to have significant positive correlations with biomass. The most significant 
was CDR1, which was unsurprising as it has been shown to be transiently expressed in 
different biofilm studies, though does not correspond directly to antifungal resistance [41,42]. 
PLB1 was showed to be significantly correlated with another 16 genes including biomass, 
though expression appeared constitutively low level within the biofilm, which is agreement 
with previous studies [39], and may have an accessory role in the degradation of host tissue 
alongside SAP’s. Of these, SAP5 was shown to be highly expressed in mature biofilms, and 
correlated with biomass and 13 other genes. We previously reported that SAP5 was 
associated with higher levels of expression in in vitro biofilms formed from denture 
stomatitis C. albicans isolates [43]. In addition, Nailis and colleagues demonstrated its crucial 
role both in a reconstituted human epithelial model and within in vivo biofilms [39]. 
Furthermore, the role of Sap5 in biofilm formation has recently been demonstrated in BSI, 
where its expression was significantly increased when compared to planktonic counterparts 
[44]. Adhesins, such as ALS3 was also upregulated, which has previously been identified to 
be involved in biofilm formation, particularly at early stages of biofilm development (0–6 h) 
[45,46], where C. albicans mutants lacking this gene produce sparse biofilms on catheter 
material in vitro [47]. EAP1, though showing no clear independent association with biofilm 
formation per se, did show a clear correlation with biomass and 11 other genes. Its 
importance in biofilm formation has been reported previously [48]. Of interest was the 
positive correlation with ZAP1 expression at 4 h, which is a negative regulator of matrix 
production [49]. It did positively correlate with BCR1, the global regulator of biofilm 
formation, suggesting that the early interaction between their proteins may be important for 
downstream construction of the biofilm. Collectively the data highlighted the importance of 
looking at multiple genes at once opposed to single gene targets. 
Conclusions 
Overall, we have categorised isolates based on biological properties relating to biofilm 
characteristics, and evaluated these in models of infection and treatment, where we have 
shown clear differences in virulence. In an attempt to create a molecular basis of categorising 
these strains we have used gene expression studies, and showed that individual gene 
expression analysis of the biofilm related genes to differentiate and categorise biofilm-
forming isolates may be futile. Instead, we have shown that taking a defined panel of genes 
during early biofilm growth may be more informative. In particular, the panel of genes such 
as SAP5, HWP1, EAP1, PLB1 and CDR1 investigated in tandem could constitute an 
important step towards diagnostics of C. albicans biofilm formation, though the use of 
transcriptomics, such as RNA-Seq, may prove useful in identifying novel diagnostic targets. 
Further work is required to determine why some patients succumb to C. albicans biofilms 
whereas others do not, as the HBF isolates do have an increased pathogenic potential and are 
more difficult to manage with antifungal agents. 
Methods 
Culture conditions and standardisation 
Candida albicans SC5314, 3153A and a series of routine patient anonymised clinical 
bloodstream isolates (n = 42) collected under the approval of the NHS Scotland Caldicott 
Gaurdians from the Royal Hospital for Sick Children (Yorkhill Division), Glasgow, UK, as 
part of candidaemia epidemiology surveillance study. All clinical isolates obtained during 
this period were independently identified using Colorex Candida chromogenic plates (E&O 
Laboratories Ltd, Bonnybridge, UK) and were stored in Microbank® vials (Pro-Lab 
Diagnostics, Cheshire, UK) at −80°C until further use. These isolates were sub-cultured onto 
Sabouraud’s dextrose agar (SAB [Sigma-Aldrich, Dorset, UK]). Plates were incubated at 
30°C for 48 h and maintained at 4°C. Isolates were propagated in yeast peptone dextrose 
(YPD) medium (Sigma-Aldrich, Dorset, UK), washed by centrifugation and resuspended in 
the appropriate media (Sigma-Aldrich) to the desired concentration, as described previously 
[50]. 
Characterisation of Candida albicans biofilm formation by clinical isolates 
All C. albicans clinical isolates (n = 42) were standardised to 1 × 106 cells/mL in RPMI-1640 
and biofilms grown in flat-bottomed 96 well microtitre plates at 37°C for 24 h and biomass of 
each isolate assessed using the crystal violet (cv) assay as previously reported [17], and 
isolates were grouped based on their level of biomass distribution (OD570nm values). Isolates 
that fell below the 1st quartile (Q1) were classed as having low biofilm formation (LBF), 
strains with a biomass greater than the 3rd quartile (Q3) were deemed isolates with high 
biofilm formation (HBF), and those that lay in between were classified as intermediate 
biofilm formation (IBF Q2). C. albicans biomass was further assessed using dry weight 
measurements. Selected isolates with LBF and HBF were grown as biofilms in 12 well tissue 
culture plates for 24 h, as previously described, and the resulting biomass homogenised in 1 
mL of PBS using a cell scraper (STARLAB, Milton Keynes, UK). This was then passed 
through a 0.22 µm filter disc (Satorius Stedim) using a vacuum and filters were dried at 40°C 
overnight before measuring each isolates dry weight. Uninoculated controls were used for 
background correction. 
Biofilm visualisation 
Representative isolates were also grown within 12 well flat-bottomed tissue culture plates 
(Corning Incorporated, NY, USA) for 24 h before carefully washing with PBS, stained with 
cv and then digitally imaged (Canon IXUS 220 HS). For scanning electron microscopy 
(SEM) representative C. albicans clinical isolates defined as LBF and HBF were grown 
directly onto Thermanox™ coverslips (Nunc, Roskilde, Denmark), then processed and 
analysed as previously described [51]. 
Cellular surface hydrophobicity assay 
The cell surface hydrophobicity (CSH) was determined for selected C. albicans clinical 
isolates with LBF (n = 10) and HBF (n = 10). CSH was assessed using the microbial 
adhesion to hydrocarbon test, with a few modifications [52,53]. Isolates were standardised to 
1 × 106 cells/mL in RPMI-1640 and grown as biofilms for 4 and 24 h in 75 cm2 flasks (Nunc, 
Rochester, NY) at 37°C. These were then washed with PBS and the resultant biomass scraped 
off and homogenised in YPD. Cells were standardised (OD590nm 1.0) and cells transferred into 
a glass tube and overlaid with 1/5th volume of xylene. Contents were vortexed for 1 min and 
phases separated over 30 min. The aqueous phase was carefully removed and OD590nm 
measured. The percentage of hydrophobicity was calculated as ([OD590nm before xylene 
overlay - OD590nm after xylene overlay]/ OD590nm before xylene overlay) × 100%. 
Antifungal susceptibility testing of biofilms 
Antifungal testing to determine minimum inhibitory concentration (MIC) of sessile cells was 
performed using voriconazole (VRZ) and amphotericin B (AMB) (Sigma-Aldrich, 
Gillingham, UK) on 24 h preformed biofilms, as previously described in flat-bottomed, 96 
well microtitre plates [50]. C. albicans LBF (n = 10) and HBF (n = 10) were tested in 
duplicate, on three separate occasions. Sessile minimum inhibitory concentrations (SMICs) 
were determined at 80% inhibition using an XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-
phenyl)-2H-tetrazolium-5-caboxanilide) metabolic reduction assay [11]. 
Galleria mellonella pathogenicity assay 
The pathogenicity of C. albicans isolates pre-defined as LBF (n = 3) and HBF (n = 3) were 
assessed using the G. mellonella killing assay, as described previously [54]. This biological 
model has been shown previously to be useful in the study of fungal virulence [32,55,56]. 
Sixth-instar G. mellonella larvae (Livefoods Direct Ltd, UK) were stored in the dark and used 
within 7 days of shipment. Ten random larvae with a bodyweight of between 200 to 300 mg 
were used for each group. Overnight YPD cultures of each isolate were washed and 
standardised to 1 × 107 cells/mL in PBS. Larvae were inoculated using a 50-µl Hamilton 
syringe with 26 g needle by injecting 10 µL aliquots (1 × 105 cells/larva) into the haemocoel, 
through the hindmost proleg. In addition, mock inoculated larvae pierced on the proleg with a 
sterile needle and a PBS inoculated control group were also included in each experiment. The 
infected larvae were placed in sterile petri dishes, incubated at 37°C and the number of dead 
larvae were scored daily. Larva was considered dead when it displayed no movement in 
response to touch together with a dark discolouration of the cuticle. Pathogenicity of LBF and 
HBF was assessed using a Kaplan-Meier plot with percentage survival monitored over 7 
days. 
Histology analysis of infected Galleria mellonella 
The morphology of the larvae infected with two isolates of C. albicans LBF and HBF was 
examined. Larvae were infected with the respective strains as described previously, and after 
post-infection (24, 48 and 72 h) larvae were fixed by a direct injection of formalin into the 
haemocoel and by formalin immersion at room temperature for 24 h. Paraffin embedded 
samples were then transversally sectioned into four-micron thickness using a microtome 
(microm HM 3335H, Thermoscientific). Sections were then stained with Periodic Acid-
Schiff (PAS) to evaluate C. albicans infected cells. Whole larvae sections were examined for 
characterisation and localisation of nodules by light optical microscope visualisation (Leica 
microscope, model 020–519.502). Two larvae were processed for each isolate, carried out on 
three separate occasions. 
Transcriptional analysis of biofilm related genes 
C. albicans clinical isolates exhibiting LBF (n = 10) and HBF (n = 10) were selected for the 
analysis of genes related to biofilm formation [57]. Biofilms were grown in 24 well flat-
bottomed plates for 4 and 24 h at 37°C, as described above. Following incubation, biofilms 
were washed with PBS, removed and homogenised using a bead beater, and RNA extracted 
using the TRIzol™ (Life Technologies, Paisley, UK) method as described previously by our 
group [42]. Total RNA was DNase (Qiagen, Crawley, UK) treated and purified using an 
RNeasy MinElute clean up kit (Qiagen, Crawley, UK), as per manufacturer’s instructions. 
RNA was quantified and quality assessed using a NanoDrop spectrophotometer (ND-1000, 
ThermoScientific, Loughborough, UK). Next, cDNA was synthesised from 200 ng of total 
RNA using High Capacity RNA to cDNA kit (Life Technologies, Paisley, UK) in a 
MyCycler PCR machine (Bio-Rad Laboratories, Hertfordshire, UK), following 
manufacturers instructions. 
All primers utilised for this study for quantitative PCR (qPCR) were designed from their 
sequences obtained from the Candida Genome Database (CGD) website 
(http://www.candidagenome.org). The web-based primer design software program Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/) was used. Primers were checked for specificity to 
C. albicans using the NIH-BLAST for short or exact nucleotide sequences 
(http://www.nlm.nih.gov/BLAST/). PCR amplification efficiencies of all designed primer 
sets were optimised prior to gene expression analysis, with efficiencies of 90-110% used in 
this study. Details of the oligonucleotides primers (Eurogentec, Southampton, UK) used in 
this study are listed in Table 3. 200 ng cDNA was used in a mastermix containing SYBR® 
GreenER™ (Life Technologies, Paisley, UK), UV-treated RNase-free water and 
forward/reverse primers (10 µM), following manufacturers’ instructions. Cycle conditions 
consisted of 2 min at 50°C, 10 min at 95°C and forty cycles of 15 s at 95°C and 60 s at 60°C. 
Each parameter (LBF n = 10, HBF n = 10 at 4 and 24 h) was analysed in duplicate using 
MxProP Quantitative PCR machine and MxProP 3000 software (Stratagene, Amsterdam, 
Netherlands) and controls consisted of reactions in which reverse transcriptase template were 
absent. Gene expression was calculated using the ∆Ct method where the genes of interest 
were normalised to the housekeeping gene Act1. 
Table 3 Candida albicans primers for real time qPCR 
Gene Sequence (5' - 3') 
ALS1 F - TTCTCATGAATCAGCATCCACAA 
R - CAGAATTTTCACCCATACTTGGTTTC 
ALS3 F - CAACTTGGGTTATTGAAACAAAAACA 
R - AGAAACAGAAACCCAAGAACAACCT 
ALS5 F - CTGCCGGTTATCGTCCATTTA 
R - ATTGATACTGGTTATTATCTGAGGGAGAAA 
EAP1 F - ACCACCACCGGGTATACAAA 
R - GCCATCACATTTGGTGACAG 
HWP1 F - GCTCAACTTATTGCTATCGCTTATTACA 
R - GACCGTCTACCTGTGGGACAGT 
BCR1 F - ATTGCCACCAATACCTGCTC 
R - GGCTGTCCATGTTGTTGTTG 
CPH1 F - ACGCAGCCACAAGCTCTACT 
R - GTTGTGTGTGGAGGTTGCAC 
EFG1 F - CCAGTGGTGGCAGTAATGTG 
R - CAGTGGCAGCCTTGGTATTT 
TUP1 F - GCTTCAGGTAACCCATTGTTGAT 
R - CTTCGGTTCCCTTTGAGTTTAGG 
OCH1 F - TCATCCAATGTTGCGTGAAT 
R - TCATGATATCGCCACCTTCA 
PMR1 F - GAATCCCCGCAGACATTAGA 
R - GGGCCTGTTTTCACCAGTTA 
MNN4 F - TGAGCAATCGTCAAAACCAG 
R - GGCGGTTGTCATTTGTTGAT 
MNT2 F - CGTCAAGGTGCCTGAAGAAT 
R - GAGGAGGAGGAGGATTTTGG 
CDR1 F - GTACTATCCATCAACCATCAGCACTT 
R - GCCGTTCTTCCACCTTTTTGTA 
MDR1 F - TCAGTCCGATGTCAGAAAATGC 
R - GCAGTGGGAATTTGTAGTATGACAA 
ZAP1 F - CGACTACAAACCACCAGCTTCATC 
R - CCCCTGTTGCTCATGTTTTGTT 
ACT1 F - AAGAATTGATTTGGCTGGTAGAGA 
R - TGGCAGAAGATTGAGAAGAAGTTT 
Clustering and heat map analysis 
Differential expression of the selected genes from all isolates with LBF (n = 10) and HBF (n 
= 10) were assessed by clustering and heat map analysis using GenEx software (Exiqon, 
Vedbaek, Denmark). In brief, percentage expression data was pre-processed for log 
transformation and mean values calculated (n = 10 for both LBF and HBF) for each gene 
before heat map production. Each coloured cell in the heat map represents the variable 
expression of genes in LBF and HBF at 4 and 24 h time points. An increase in gene 
expression is represented by red and a down-regulation by green. Clustering techniques were 
used to show genes with similar expression patterns (co-regulated genes) in each set of 
isolates. The clustering was performed independently by average linkage and Euclidean 
distances used as a distance measure for both dimensions in the data. 
Statistical analysis 
Graph production, data distribution and statistical analysis were performed using GraphPad 
Prism (version 4; La Jolla, CA, USA). After assessing whether data conformed to a normal 
distribution data were transformed where necessary and One Way Analysis of Variance 
(ANOVA) was used to investigate significant differences between independent groups. A 
Bonferroni post-test was used to determine statistically significant differences between 
groups. The G. mellonella survival curve was analysed using log rank test. Student t-tests 
were used to measure statistical differences between the two independent groups assessed in 
gene expression studies. Statistical significance was achieved if p < 0.05. IBM SPSS® 
(version 20) statistical analysis software was used for correlation analysis. Two-tailed 
Spearman rho correlation coefficient was determined separately for all 4 and 24 h selected 
genes expression versus 24 h biomass data. Genes that had a significant correlation with 
biomass were tested for correlations with the other genes as described above. 
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Additional files 
Additional_file_1 as PPTX 
Additional file 1: Figure S1 Optimisation of C. albicans biofilms. Standardised C. albicans 
SC5314 and 3153A (1×106 cells/mL) were grown in flat-bottomed 96 well microtitre plates 
at 37°C for 24, 48 and 72 h in RPMI-1640, YPD + 10% FCS, YNB + 100mM glucose and 
Spider media. Negative controls were also included. Mature biofilms were carefully washed 
with PBS, air-dried and biomass quantified by staining each biofilm with 0.05% w/v crystal 
violet solution. The biofilms were washed and 100% ethanol applied to destain each biofilm. 
The biomass was quantified spectrophotometrically by reading absorbance at 570nm in a 
microtitre plate reader (FluoStar Omega, BMG Labtech). Three replicates for each isolate 
were used and carried out on two separate occasions. Data represents mean ± SEM. 
Significant differences were observed when comparing RPMI-1640 to all other growth media 
at 24 h (§§p<0.005, §§§p<0.0001), 48 h (#p<0.005, ###p<0.0001) and 72 h (†p<0.05, 
†††p<0.0001). Significant differences were also found between periods of biofilm 
development within each growth media (*p<0.05, **p<0.01). 
Additional_file_2 as DOC 
Additional file 2: Table S1 Percentage gene expression in C. albicans 4 and 24 h 
biofilms. (DOC 44 kb) 
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